QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two… Read More
RheumNow
CDC 2025–26 Updates to Influenza Vaccination. – Most are trivalent inactivated (IIV3s) or vaccines (RIV3), few live… Read More
Patient Resource: The Hidden Connection – ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about… Read More
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortali https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg… Read More
What you need to know about scleroderma-related lung fibrosis khannad@umich.edu Thu, 09/18/2025 – 11:00 Read More
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg… Read More
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial,… Read More
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%,… Read More
Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor… Read More
🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…… Read More
GLP-1 drugs cost-effective for knee osteoarthritis and obesity jjcush@gmail.com Wed, 09/17/2025 – 14:20 Read More
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurem… Read More
Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient c… Read More
Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but… Read More
Controversies in ILD tammytilley@gm… Wed, 09/17/2025 – 08:25 Education/ACR/EULAR Anti-Rheumatic Rx Novel Rx Other Rheumatoid Arthritis Cardio/Pulmonary… Read More
Significant diagnostic and treatment delays gmcdermott@bwh… Wed, 09/17/2025 – 08:00 Read More
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case… Read More
How to assess ILD in your patients? Have a high index of suspicion in your patients with… Read More
Controversies in ILD https://t.co/MtbYpDGn1w https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 19:02 RheumNow Dr. John Cush Controversies in ILD… Read More
August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort… Read More
Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor… Read More
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from… Read More
Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It… Read More
There is no criteria for infection-induced Antiphospholipid syndr (APS). aPL & aCL abs have been reported w/… Read More
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8 https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 –… Read More